Bharat Immunological
Ticker > Company >

Bharat Immunological share price

Bharat Immunologicals & Biologicals Corporation Ltd.

BSE: 524663 SECTOR: Pharmaceuticals & Drugs  52.13 K   173   14

21.70
-0.27 (-1.23%)
BSE: 10 Sep 04:01 PM

Price Summary

Today's High

₹ 22.24

Today's Low

₹ 21.53

52 Week High

₹ 35.88

52 Week Low

₹ 19

FinStar is Suspended!

The FinStar rating for this company is currently unavailable due to limited data disclosure. As a micro-cap company, it may carry higher risk and limited transparency. We will update the FinStar rating once more reliable data becomes available.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 93.7 Cr.

Enterprise Value

₹ 155.19 Cr.

No. of Shares

4.32 Cr.

P/E

0

P/B

0

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  0

CASH

₹ 8.74 Cr.

DEBT

₹ 70.22 Cr.

Promoter Holding

59.25 %

EPS (TTM)

₹  -3.85

Sales Growth

-43.09%

ROE

0 %

ROCE

-25.63%

Profit Growth

-90.08 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-43.09%
3 Year-12.61%
5 Year5.09%

Profit Growth

1 Year-90.08%
3 Year-28.17%
5 Year-213.75%

ROE%

1 Year0%
3 Year-52.88%
5 Year-43.11%

ROCE %

1 Year-25.63%
3 Year-35.58%
5 Year-27.86%

Debt/Equity

-3.0491

Price to Cash Flow

8.6

Interest Cover Ratio

-2.15427219672503

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 59.25 0.00
Dec 2023 59.25 0.00
Sep 2023 59.25 0.00
Jun 2023 59.25 0.00
Mar 2023 59.25 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has a high promoter holding of 59.25%.

 Limitations

  • The company has shown a poor profit growth of -28.1738845774293% for the Past 3 years.
  • The company has shown a poor revenue growth of -12.6082359350442% for the Past 3 years.
  • Company has a poor ROE of -52.880167346182% over the past 3 years.
  • Company has a poor ROCE of -35.5847877080558% over the past 3 years
  • The company has a low EBITDA margin of -18.702150517745% over the past 5 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2022 Sep 2022 Dec 2022 Jun 2023 Sep 2023
Net Sales 10.48 26.48 0 0 0
Total Expenditure 15.31 28.98 4.73 4.31 4.69
Operating Profit -4.83 -2.5 -4.73 -4.31 -4.69
Other Income 0.14 0.32 0.1 0.1 0.16
Interest 1.58 1.74 1.67 1.72 2.09
Depreciation 0.04 0.04 0.04 0.03 0.03
Exceptional Items 0 0 0 0 0
Profit Before Tax -6.3 -3.96 -6.33 -5.97 -6.65
Tax -1.31 -0.88 -1.65 -1.38 -1.73
Profit After Tax -5 -3.08 -4.69 -4.59 -4.92
Adjusted EPS (Rs) -1.16 -0.71 -1.09 -1.06 -1.14

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 83.65 66.84 85.33 78.39 44.61
Total Expenditure 92.96 77.23 106.2 83.36 60.68
Operating Profit -9.32 -10.4 -20.86 -4.97 -16.07
Other Income 4.22 1.18 1.68 1.1 1.06
Interest 2 4.75 4.79 5.6 7.06
Depreciation 0.28 0.24 0.24 0.21 0.2
Exceptional Items 0 0 0 0 0
Profit Before Tax -7.37 -14.2 -24.21 -9.69 -22.27
Tax -1.58 -3.99 -6.1 -0.93 -5.63
Net Profit -5.79 -10.21 -18.11 -8.75 -16.64
Adjusted EPS (Rs.) -1.34 -2.36 -4.19 -2.03 -3.85

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 43.18 43.18 43.18 43.18 43.18
Total Reserves -12.5 -22.71 -9.14 62.17 45.03
Borrowings 0 0 0 0 0
Other N/C liabilities -4.2 -8.35 -14.24 -14.91 -20.26
Current liabilities 88.48 100.71 64.09 101.26 94.04
Total Liabilities 114.95 112.83 83.89 191.7 161.99
Assets
Net Block 4.7 4.47 4.23 115.98 115.75
Capital WIP 0.22 0.22 31.9 0 0
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 1.8 1.49 1.29 1.23 1.16
Other N/C Assets 9.5 13.63 12.52 9.06 9.28
Current Assets 98.74 93.02 33.95 65.43 35.8
Total Assets 114.95 112.83 83.89 191.7 161.99
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations -7.37 -14.2 -24.21 -9.69 -22.27
Adjustment 0.04 4.08 36.03 5.27 6.32
Changes in Assets & Liabilities -24.76 44.21 -0.04 -37.7 26.84
Tax Paid 0 0 0 0 0
Operating Cash Flow -32.1 34.08 11.78 -42.12 10.89
Investing Cash Flow 0.7 0.91 0.67 0.53 0.46
Financing Cash Flow 30.61 -34.41 -12.2 45 -14.71
Net Cash Flow -0.79 0.58 0.24 3.42 -3.36

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 59.25 59.25 59.25 59.25 59.25
president of india 59.25 59.25 59.25 59.25 59.25
PARTICULARS Mar 2021%
investors 40.75
topgain finance private l... 1.05

Annual Reports

Title Link
Title Link
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Bharat Immunological Stock Price Analysis and Quick Research Report. Is Bharat Immunological an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Bharat Immunological. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Bharat Immunological has a PE ratio of -5.63139046037266 which is low and comparatively undervalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Bharat Immunological has ROA of -9.40858216181723% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Bharat Immunological has a Current ratio of 0.38071165847709.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Bharat Immunological has a ROE of 0%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Bharat Immunological has a Debt to Equity ratio of -3.0491 which means that the company has low proportion of debt in its capital.

  • Sales growth: Bharat Immunological has reported revenue growth of -43.0919273358167% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Bharat Immunological for the current financial year is -36.0213499039434%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Bharat Immunological is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Bharat Immunological is Rs -3.8534. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Bharat Immunological in Ticker for free. Also, one can get the intrinsic value of Bharat Immunological by using Valuation Calculators, which are available with a Finology ONE subscription. 

Bharat Immunological FAQs

Q1. What is Bharat Immunological share price today?
Ans: The current share price of Bharat Immunological is Rs 21.7.

Q2. What is the market capitalisation of Bharat Immunological?
Ans: Bharat Immunological has a market capitalisation of Rs 93.7006 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Bharat Immunological?
Ans: The PE ratio of Bharat Immunological is -5.63139046037266 and the P/B ratio of Bharat Immunological is 0, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Bharat Immunological share?
Ans: The 52-week high share price of Bharat Immunological is Rs 35.88, and the 52-week low share price of Bharat Immunological is Rs 19.

Q5. Does Bharat Immunological pay dividends?
Ans: Currently, Bharat Immunological does not pay dividends. Dividend yield of Bharat Immunological is around 0%.

Q6. What are the face value and book value of Bharat Immunological shares?
Ans: The face value of Bharat Immunological shares is Rs 10, while the book value per share of Bharat Immunological is around Rs 0. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Bharat Immunological?
Ans: Bharat Immunological has a total debt of Rs 70.2249 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Bharat Immunological?
Ans: The ROE of Bharat Immunological is 0% and ROCE of Bharat Immunological is -25.6278125708277%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Bharat Immunological a good buy for the long term?
Ans: The Bharat Immunological long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Bharat Immunological undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Bharat Immunological appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Bharat Immunological’s financials?
Ans: You can review Bharat Immunological’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Bharat Immunological
X